

September 10, 2010
Ono Pharmaceutical Co., Ltd.
Astellas Pharma Inc.

Application for RECALBON[®] Tablets 50mg/ Bonoteo[®] Tablets 50mg,
A Monthly Oral Osteoporosis Treatment in Japan

Osaka and Tokyo, Japan, September 10, 2010 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced the submission of a market authorization application for RECALBON[®] Tablets 50mg (Ono) / Bonoteo[®] Tablets 50mg (Astellas) (generic name: minodronic acid hydrate) to Pharmaceuticals and Medical Devices Agency today in Japan.

Minodronic acid hydrate is an oral bisphosphonate that has been discovered by Astellas and has been co-developed by Ono and Astellas. This drug increases the bone mineral density and the strength by inhibiting osteoclastic bone resorption. RECALBON[®] Tablets 1mg / Bonoteo[®] Tablets 1mg, a daily formulation of this drug, demonstrated a significant efficacy in bone fractures prevention, and launched in April, 2009 in Japan. RECALBON[®] Tablets 50mg / Bonoteo[®] Tablets 50mg, a monthly formulation of this drug, demonstrated non-inferiority to the daily formulation 1 mg in average bone mineral density change in lumbar spines, the primary endpoint in a Phase 2 / 3 study in Japan. Furthermore, based on the safety results in the Phase 2 / 3 study, monthly formulation 50 mg appeared to be safe, and the incidence of side-effects was low and comparable to the daily formulation 1 mg. Therefore, a monthly formulation 50mg is expected to have an equivalent effect in bone fractures prevention to the daily formulation and boost the patients’ convenience by reducing the dose frequency.

Since the launch of RECALBON[®] Tablets 1mg / Bonoteo[®] Tablets 1mg in Japan, Ono and Astellas have contributed to the improvement of the quality of life of the patients suffering from osteoporosis through the prevention of bone fractures. The both companies expect to provide a new therapeutic option to the current osteoporosis treatment in addition to RECALBON[®] Tablets 1mg / Bonoteo[®] Tablets 1mg, and believe to contribute further to the patients by introducing RECALBON[®] Tablets 50mg / Bonoteo[®] Tablets 50mg into the Japanese market.

#####

Contacts for inquiries or additional information
--

Ono Pharmaceutical Co., Ltd.

Corporate Communications

Tel: +81-6-6263-5670 Fax: +81-6-6263-2950

http://www.ono.co.jp/

Astellas Pharma Inc.

Corporate Communications

Tel: +81-3-3244-3201 Fax: +81-3-5201-7473

http://www.astellas.com/en
